PHOENIX, Oct. 10, 2018 /PRNewswire/ — 4Front Holdings, LLC (“4Front”), a leading retail and brand development company in the U.S. cannabis sector, today announced the appointment of David Nathan, MD, DFAPA, as Chief Medical Advisor. In addition, Dr. Nathan will serve as a liaison to the Advisory Board for MissionTM, 4Front’s branded network of medical marijuana dispensaries, to ensure professional medical expertise remains central to 4Front’s overall operations.
Dr. Nathan brings to 4Front a wealth of experience not only as a medical advocate for evidence-based cannabis policy, but also as a psychiatrist, writer, speaker, and educator. He is a Distinguished Fellow of the American Psychiatric Association, an honor awarded to psychiatrists who have made significant contributions to the psychiatric profession, and a Clinical Associate Professor of Psychiatry at Rutgers Robert Wood Johnson Medical School. He is also the founder and board president of Doctors for Cannabis Regulation (DFCR) and was one of the founding steering committee members of New Jersey United for Marijuana Reform. Dr. Nathan was the first physician in New Jersey history to testify in favor of marijuana legalization before the state legislature, and has offered testimony in several other states. He has traveled around the country speaking to physicians, patient groups, industry leaders, government officials and the general public about cannabis as medicine and cannabis policy reform.
The growth of the cannabis industry is unlike anything we’ve seen before, and that’s why it’s imperative that as the industry expands, conversations around patient advocacy and care must be at the forefront of that expansion. I am extremely excited to join 4Front’s leadership team and help them in their mission to educate the nation on the promise of medical cannabis.
David Nathan, Chief Medical Advisor at 4Front
As Chief Medical Advisor, Dr. Nathan will keep 4Front abreast of new scientific research related to medical cannabis, and offer strategic guidance as it relates to all aspects of patient care, cannabis research, medical safety, medical compliance and administration of cannabis as a medicine. Additionally, Dr. Nathan will provide leadership and oversight for training for Mission’s staff as it relates to patient care and medical safety, and for the development and dissemination of educational materials for patients and caregivers. Dr. Nathan will also engage medical professionals through outreach and educational offerings regarding the use of cannabis as a medicine.
“We’re pleased to welcome Dr. Nathan to our senior leadership team, and we expect his impeccable and proven track record and thoughtful approach to effective legalization and regulation of medical marijuana will be valuable assets for 4Front,” said Kris Krane, President of 4Front. “This important and timely addition to our clinical team underscores 4Front’s progress and longstanding commitment to patient advocacy as it relates to safety, medical compliance and the administration of cannabis as medicine, keeping it as one of 4Front’s highest priorities.”
Dr. Nathan graduated magna cum laude from Princeton University, received his M.D. from the University of Pennsylvania School Of Medicine, and completed his psychiatry residency at McLean Hospital of Harvard Medical School.
4Front Holdings, LLC (“4Front”) is a leading retail and brand development company in the U.S. cannabis sector. It has developed a national platform that consists of a multi-state footprint, including its Mission-branded retail operations, and a far-reaching network of partnership relationships. Led by a group of professionals with experience in finance, real estate, manufacturing, and multi-location retail and hospitality operations, 4Front has invested heavily in assembling a team with the management skills and hands-on operating expertise that can support the rapid operational growth opportunity being afforded by the increased legalization of cannabis across the United States, as well as internationally. For more information, visit the website.